13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q4 2017. See the latest, Q3 2026 →

Reported value

$10.11B

+26% on the quarter before

Positions

34

2 new, 5 sold out

Top 10

75.3%

of the value

Est. gain

+$466.4M

on stocks held all quarter

Est. return

+6.3%

on those stocks since Q3 2017

Filed

Feb 13, 2018

On SEC EDGAR ↗

Positions as of Dec 31, 2017, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2017. Striped tiles are options.

Synchrony Finl11%
Cheniere Energy Inc11%
Viasat Inc9.7%
Twenty First Centy Fox Inc7.6%
Time Warner Inc7.3%
Allergan Plc7.3%
Qorvo7.2%
Colony Northstar Inc5.4%
Antero Res Corp4.6%
Pbf Energy Inc3.8%
Twenty First Centy Fox Inc3.6%
Pioneer Nat Res Co3.4%
Cardinal Health Inc3.1%
Theravance Biopharma Inc2.6%
Mckesson Corp2.1%
10 others1.8%
Express Scripts Hldg Co1.7%
Amerisourcebergen Corp1.3%
Keryx Biopharmaceuticals Inc1.2%
Veritiv Corp1.0%
Atara Biotherapeutics Inc1.0%
0.7%

Largest buys

Since Q3 2017, sized at quarter-end prices.

  1. Time Warner Inc~$740.9MNew, 0.0% → 7.3% of the portfolio+8,100,000 shares
  2. Pioneer Nat Res Co~$340.7MAdded, 0.1% → 3.4% of the portfolio+1,971,105 shares
  3. Allergan Plc~$251.2MAdded, 7.6% → 7.3% of the portfolio+1,535,797 shares
  4. Cardinal Health Inc~$157.5MAdded, 2.1% → 3.1% of the portfolio+2,570,000 shares
  5. Mckesson Corp~$134.1MAdded, 1.0% → 2.1% of the portfolio+860,000 shares
  6. Qorvo~$133.2MAdded, 7.9% → 7.2% of the portfolio+2,000,000 shares
  7. Amerisourcebergen Corp~$114.4MAdded, 0.2% → 1.3% of the portfolio+1,245,715 shares
  8. Twenty First Centy Fox Inc~$108.8MAdded, 6.3% → 7.6% of the portfolio+3,151,262 shares
  9. Twenty First Centy Fox Inc~$107.4MAdded, 2.4% → 3.6% of the portfolio+3,146,716 shares
  10. Amc Entmt Hldgs Inc~$21.7MAdded, 0.7% → 0.7% of the portfolio+1,434,639 shares

Largest sells

Since Q3 2017, sized at quarter-end prices.

  1. Dell Technologies Inc~$235.7MSold out, 2.9% → 0.0% of the portfolio−3,052,459 shares
  2. Pbf Energy Inc~$170.2MCut, 5.4% → 3.8% of the portfolio−4,800,000 shares
  3. Centennial Resource Dev Inc~$42.1MSold out, 0.5% → 0.0% of the portfolio−2,407,153 shares
  4. Avis Budget Group~$39.5MSold out, 0.5% → 0.0% of the portfolio−1,036,900 shares
  5. ChipMOS Technologies~$27.9MCut, 0.7% → 0.3% of the portfolio−1,577,887 shares
  6. Silver Run Acquisition~$21.9MSold out, 0.3% → 0.0% of the portfolio−2,149,352 shares
  7. Express Scripts Hldg Co~$18.7MCut, 2.0% → 1.7% of the portfolio−250,435 shares
  8. Forward Pharma A/S~$8.4MCut, 0.5% → 0.2% of the portfolio−2,283,325 shares
  9. Simply Good Foods Co~$2.5MSold out, 0.0% → 0.0% of the portfolio−1,035,146 shares

Holdings

As of Dec 31, 2017; changes in shares since Sep 30, 2017.

Positions, sorted by share of the portfolio
HoldingValue
Synchrony FinlCOM · shares 0% · price +24.3%11.2%$1.13B+$221.5M
Cheniere Energy IncCOM NEW · shares 0% · price +19.5%11.0%$1.12B+$182.4M
Viasat IncCOM · shares 0% · price +16.4%9.7%$984.9M+$138.6M
Twenty First Centy Fox IncCL A · shares +16% · price +30.9%7.6%$769.6M+$156.0M
Time Warner IncCOM NEW · shares New7.3%$740.9M—
Allergan PlcSHS · shares +52% · price −20.2%7.3%$736.1M−$122.6M
QorvoCOM · shares +22% · price −5.8%7.2%$732.6M−$36.7M
Colony Northstar IncCL A COM · shares 0% · price −9.2%5.4%$546.6M−$55.1M
Antero Res CorpCOM · shares +3.4% · price −4.5%4.6%$469.7M−$21.5M
Pbf Energy IncCL A · shares −31% · price +28.4%3.8%$387.3M+$85.6M
Twenty First Centy Fox IncCL B · shares +43% · price +32.3%3.6%$359.3M+$61.5M
Pioneer Nat Res CoCOM · shares +6,822% · price +17.2%3.4%$345.7M+$731,501
Cardinal Health IncCOM · shares +102% · price −8.4%3.1%$312.5M−$14.3M
Theravance Biopharma IncCOM · shares 0% · price −18.5%2.6%$259.6M−$59.1M
Mckesson CorpCOM · shares +172% · price +1.5%2.1%$212.1M+$1.2M
Express Scripts Hldg CoCOM · shares −9.8% · price +17.9%1.7%$172.2M+$26.1M
Amerisourcebergen CorpCOM · shares +660% · price +11.0%1.3%$131.7M+$1.7M
Keryx Biopharmaceuticals IncCOM · shares 0% · price −34.5%1.2%$119.9M−$63.2M
Veritiv CorpCOM · shares +19% · price −11.1%1.0%$105.2M−$11.0M
Atara Biotherapeutics IncCOM · shares 0% · price +9.4%0.96%$97.0M+$8.3M
Amc Entmt Hldgs IncCL A COM · shares +40% · price +2.7%0.75%$75.5M+$1.4M
Gty Technology Holdings IncUNIT 99/99/9999 · shares 0% · price −1.4%0.45%$45.4M−$645,000
Paratek Pharmaceuticals IncCOM · shares 0% · price −28.7%0.42%$42.9M−$17.2M
Novagold Res IncCOM NEW · shares +13% · price −4.6%0.42%$42.2M−$1.8M
Theravance Biopharma IncNOTE 3.250%11/0 · shares 0% · price −11.0%0.33%$33.0M—
Total 34 positions100%$10.11B+$466.4M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q3 2017 to Q4 2017: 31 stocks held throughout, up $466.4M (+6.3%).

  1. Synchrony Finl+$221.5M+24%
  2. Cheniere Energy Inc+$182.4M+20%
  3. Twenty First Centy Fox Inc+$156.0M+31%
  4. Viasat Inc+$138.6M+16%
  5. Pbf Energy Inc+$85.6M+28%
  6. Qorvo−$36.7M−6%
  7. Colony Northstar Inc−$55.1M−9%
  8. Theravance Biopharma Inc−$59.1M−19%
  9. Keryx Biopharmaceuticals Inc−$63.2M−35%
  10. Allergan Plc−$122.6M−20%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free